Exeter Automobile Receivables Trust 2022-3 has filed its latest monthly distribution report, revealing that no assets securitized by Exeter Finance LLC were subject to repurchase demands during the reporting period from September 1, 2026, to September 30, 2026. This update is significant as it highlights the trust's stability and performance in the asset-backed securities market.
Exeter Automobile Receivables Trust 2022-3 is categorized under the Standard Industrial Classification (SIC) of 6189, which pertains to asset-backed securities. The trust operates under the auspices of Exeter Finance LLC, which serves as the servicer for the trust. The recent filing, dated October 29, 2026, is part of a series of reports that the trust has submitted, including the 10-D and ABS-EE forms.
The filing confirms that during the distribution period, there were no demands for repurchase due to breaches of representations and warranties. This is a positive indicator for the trust, suggesting that the underlying auto loans are performing well. The report also includes asset-level information, which is essential for investors looking to assess the performance of the trust's assets.
This report may affect various stakeholders in the asset-backed securities market, including investors, analysts, and competitors. The absence of repurchase demands signals confidence in the trust's management and the quality of its underlying assets, which could influence investor sentiment and market dynamics.
Looking ahead, the filing does not specify what actions will follow this report. However, it is likely that the trust will continue to monitor its asset performance closely and provide updates in future filings.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










